Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 30:13:933847.
doi: 10.3389/fimmu.2022.933847. eCollection 2022.

Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

Affiliations
Review

Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation

Chiel van Geffen et al. Front Immunol. .

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population with potent suppressive and regulative properties. MDSCs' strong immunosuppressive potential creates new possibilities to treat chronic inflammation and autoimmune diseases or induce tolerance towards transplantation. Here, we summarize and critically discuss different pharmacological approaches which modulate the generation, activation, and recruitment of MDSCs in vitro and in vivo, and their potential role in future immunosuppressive therapy.

Keywords: MDSC; immune suppression; immunomodulation; inflammation; pharmacotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of possible pharmacological targets for the induction of MDSCs. Proliferation and activation of MDSCs is regulated by transcription factors such as signal transducer and activator of transcription (STAT) 3, STAT1, STAT5, STAT6 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). In vitro generation of MDSCs is induced by a large variety of cytokines and cytokine combinations and lactoferrin. MDSC generation may be followed by adoptive transfer cell therapy to induce the beneficial effects of MDSCs. Various compounds [e.g. rapamycin, glucocorticoids, terbutaline, tofacitinib, glatirameracetat, cannabidiol, clarithromycin, taurodeoxycholate, CXCR1 or CXCR2 ligands, complete Freund’s adjuvant (CFA), membrane vesicles (MV), Toll-like receptor (TLR) 2/4 agonistic antibodies, prostaglandin E2, cyclosporine A and receptor interacting protein kinase (RIPK) 3 inhibitor (GSK 872)] may be used for accumulation of MDSCs in vivo. G-CSF granulocyte colony-stimulating factor, M-CSF macrophage CSF, GM-CSF granulocyte-macrophage CSF, IL Interleukin, TNF tumor necrosis factor, TGF transforming growth factor, VEGF vascular endothelial growth factor, IFN interferon, mTOR mammalian target of rapamycin, JAK Janus kinase, LRP lactoferrin receptor, iNOS inducible nitric oxide synthase, Arg arginase, IDO indoleamine 2,3-dioxygenase, NADPH nicotiamide adenine dinucleotide phosphate, NFAT nuclear factor of activated t cells, p phosphorylated, CXCR CXC chemokine receptors, COX cyclooxygenase.

Similar articles

Cited by

References

    1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162–74. doi: 10.1038/nri2506 - DOI - PMC - PubMed
    1. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. . Identification of a Cd11b(+)/Gr-1(+)/Cd31(+) myeloid progenitor capable of activating or suppressing Cd8(+) T cells. Blood (2000) 96(12):3838–46. doi: 10.1182/blood.V96.12.3838 - DOI - PMC - PubMed
    1. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 13(10):739–52. doi: 10.1038/nrc3581 - DOI - PMC - PubMed
    1. Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, et al. . Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight (2019) 4(7):e126853. doi: 10.1172/jci.insight.126853 - DOI - PMC - PubMed
    1. Albeituni SH, Ding C, Yan J. Hampering immune suppressors: Therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 19(6):490–501. doi: 10.1097/PPO.0000000000000006 - DOI - PMC - PubMed

Publication types